{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:16:03Z","timestamp":1771841763847,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.4158\/ep13164.or","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T22:40:01Z","timestamp":1378507201000},"page":"145-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Third-Generation Elisa Thyrotropin-Receptor Antibody Levels as an Adjuvant Tool to Guide Management of Patients with Graves Orbitopathy"],"prefix":"10.1016","volume":"20","author":[{"given":"Ravit","family":"Tvito-Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehud","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal","family":"Robenshtok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonina","family":"Ron-Kella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas","family":"Stiebel-Kalish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP13164.OR_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP13164.OR_bb0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol."},{"key":"10.4158\/EP13164.OR_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"European Group on Graves\u2019 Orbitopathy (EUGOGO)","year":"2006","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP13164.OR_bb0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2010.0417","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and the American Association of Clinical Endocrinologists","volume":"21","author":"Bahn","year":"2011","journal-title":"Thyroid."},{"key":"10.4158\/EP13164.OR_bb0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1507\/endocrj.K06-196","article-title":"TSH-receptor antibodies determined by the first, second and third generation assays and thyroid-stimulating antibody in pregnant patients with Graves\u2019 disease","volume":"54","author":"Kamijo","year":"2007","journal-title":"Endocr J."},{"key":"10.4158\/EP13164.OR_bb0030","doi-asserted-by":"crossref","unstructured":"Theodoraki A, Jones G, Parker J, et al. Performance of a third generation TSH-receptor antibody (TRAb) in a UK clinic. Clin Endocrinol (Oxf). 2011; Feb 19. [Epub ahead of print].","DOI":"10.1111\/j.1365-2265.2011.04022.x"},{"key":"10.4158\/EP13164.OR_bb0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/1050725042451248","article-title":"A new assay for thyrotropin receptor autoantibodies","volume":"14","author":"Smith","year":"2004","journal-title":"Thyroid."},{"key":"10.4158\/EP13164.OR_bb0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9394(77)90140-4","article-title":"Modification of the classification of the eye changes of Graves\u2019 disease","volume":"83","author":"Werner","year":"1977","journal-title":"Am J Ophthalmol."},{"key":"10.4158\/EP13164.OR_bb0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2265.2000.00973.x","article-title":"Assessment of disease activity in Graves\u2019 ophthalmopathy by orbital ultrasonography and clinical parameters","volume":"52","author":"Gerding","year":"2000","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP13164.OR_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00417-009-1214-3","article-title":"A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves orbitopathy","volume":"248","author":"Johnson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"10.4158\/EP13164.OR_bb0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5301\/ejo.5000018","article-title":"Graves\u2019 orbitopathy: extraocular muscle\/total orbit area ratio is positively related to the Clinical Activity Score","volume":"22","author":"Le Moli","year":"2012","journal-title":"Eur J Ophthalmol."},{"key":"10.4158\/EP13164.OR_bb0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejim.2011.02.006","article-title":"The role of TSH receptor antibodies in the management of Graves\u2019 disease","volume":"22","author":"Matthews","year":"2011","journal-title":"Eur J Intern Med."},{"key":"10.4158\/EP13164.OR_bb0065","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1089\/105072502761016467","article-title":"Reduction of the risk of relapse after withdrawal of medical therapy for Graves\u2019 disease","volume":"12","author":"Orgiazzi","year":"2002","journal-title":"Thyroid."},{"issue":"suppl 2","key":"10.4158\/EP13164.OR_bb0070","first-page":"198","article-title":"Clinical value of TSH receptor antibodies measurement in patients with Graves\u2019 orbitopathy","volume":"7","author":"Eckstein","year":"2010","journal-title":"Pediatr Endocrinol Rev."},{"key":"10.4158\/EP13164.OR_bb0075","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","article-title":"A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy","volume":"95","author":"Lytton","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP13164.OR_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/thy.2008.0034","article-title":"The EUGOGO consensus statement on the management of Graves\u2019 orbitopathy: equally applicable to North American clinicians and patients","volume":"18","author":"Bahn","year":"2008","journal-title":"Thyroid."},{"key":"10.4158\/EP13164.OR_bb0085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"17","author":"Bahn","year":"2011","journal-title":"Endocr Pract."},{"key":"10.4158\/EP13164.OR_bb0090","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1172\/JCI0216991","article-title":"A monoclonal thyroid-stimulating antibody","volume":"110","author":"Ando","year":"2002","journal-title":"J Clin Invest."},{"key":"10.4158\/EP13164.OR_bb0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-2007-978858","article-title":"Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor","volume":"30","author":"Morgenthaler","year":"1998","journal-title":"Horm Metab Res."},{"key":"10.4158\/EP13164.OR_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/ncpendmet0886","article-title":"Techniques to quantify TSH receptor antibodies","volume":"4","author":"Ajjan","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"10.4158\/EP13164.OR_bb0105","unstructured":"Medizinische Labordiagnostika AG. Anti TSH receptor (TRAb) fast ELISA IgG. Available at: http:\/\/www.euroimmun.com\/index.php?id=aak_gegen_schilddruesenantigene&L=1. Accessed December 18, 2013."},{"key":"10.4158\/EP13164.OR_bb0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cca.2008.11.025","article-title":"Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies","volume":"401","author":"Hermsen","year":"2009","journal-title":"Clin Chim Acta."},{"key":"10.4158\/EP13164.OR_bb0115","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1055\/s-0029-1243057","article-title":"Management of Graves\u2019 orbitopathy: evidence-based recommendations","volume":"134","author":"Ponto","year":"2009","journal-title":"Dtsch Med Wochenschr."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20437401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20437401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/9R1W42Q2G6146868.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:56:16Z","timestamp":1761515776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20437401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1530891X20437401"],"URL":"https:\/\/doi.org\/10.4158\/ep13164.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-Generation Elisa Thyrotropin-Receptor Antibody Levels as an Adjuvant Tool to Guide Management of Patients with Graves Orbitopathy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13164.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}